Stocktoria
Sight Sciences, Inc. SGHT
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-07-15
Sight Sciences, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M | $27.6M |
| Gross profit | $66.7M | $68.3M | $69.2M | $59.0M | $40.3M | $18.4M |
| R&D expense | $14.6M | $18.0M | $17.6M | $22.9M | $15.6M | $8.9M |
| SG&A expense | $89.2M | $100.8M | $108.9M | $120.1M | $76.2M | $41.7M |
| Operating income | -$37.1M | -$50.5M | -$57.3M | -$84.0M | -$51.5M | -$32.2M |
| Interest expense | $5.1M | $4.7M | $5.4M | $4.5M | $4.4M | $2.4M |
| Income tax | $10,000 | $236,000 | $110,000 | $47,000 | $188,000 | $61,000 |
| Net income | -$38.4M | -$51.5M | -$55.5M | -$86.2M | -$63.0M | -$34.7M |
| EPS (diluted) | $-0.74 | $-1.03 | $-1.14 | $-1.80 | $-2.36 | — |
| Operating cash flow | -$29.7M | -$22.4M | -$47.2M | -$76.0M | -$52.5M | -$32.2M |
| Free cash flow | -$29.9M | -$22.7M | -$48.0M | -$76.9M | -$53.4M | -$33.1M |
| Cash & equivalents | $92.0M | $120.4M | $138.1M | $185.0M | $260.7M | $61.5M |
| Inventory | $7.8M | $6.3M | $7.8M | $6.1M | $3.5M | $2.6M |
| Total assets | $115.3M | $142.8M | $166.7M | $213.1M | $280.2M | $72.8M |
| Total liabilities | $51.4M | $55.3M | $46.4M | $53.0M | $48.1M | $44.3M |
| Shareholders' equity | $63.9M | $87.5M | $120.2M | $160.1M | $232.1M | -$88.8M |
Growth · year-over-year · Revenue CAGR 22.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -3.1% | -1.5% | +13.6% | +45.7% | +77.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.